Almonte Maribel, Ferreccio Catterina, Luciani Silvana, Gonzales Miguel, Delgado Jose M, Santos Carlos, Alvarez Manuel, Cuzick Jack, Sasieni Peter
International Agency for Research on Cancer, Lyon, France; Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom.
Advanced Center for Chronic Diseases, ACCDIS-FONDAP, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
PLoS One. 2015 Jan 30;10(1):e0115355. doi: 10.1371/journal.pone.0115355. eCollection 2015.
Conventional cytology (Pap) and visual inspection after the application of acetic acid (VIA) are currently used in primary screening in Peru. Studies suggest that the quality of VIA is highly variable. Over 36 000 women were screened with Pap and VIA in the TATI (Tamizaje y Tratamiento Inmediato de Lesiones Cervico-uterinas) project conducted in Amazonian Peru. Within a nested study to compare several screening techniques (C-TATI), a total of 5435 women were additionally screened with liquid-based cytology (LBC) and high-risk human papillomavirus testing (HR-HPV). We investigate the variation of positivity rates of VIA, Pap, LBC and HR-HPV in C-TATI and of VIA in the full TATI intervention.
At the screening visit, midwives collected three cervical samples for Pap, LBC and HC2 before performing VIA. The dispersion factor "D" (D = Pearson chi-square value/degrees-of-freedom) was used to measure the variability of tests results. Within C-TATI, the variability of positivity rates of VIA, Pap, LBC and HR-HPV was also graphically assessed with box- and scatter plots by midwife and month of screening. Funnel plots and smoothed scatter plots were used to correlate the variation of VIA by the number of examinations performed by each midwife over the full TATI intervention.
Consistently over TATI, VIA results were highly variable, independently of the examiner, the time when the test was performed and the number of tests the examiner performed (D>6, p-values<0.001). In C-TATI, VIA results varied the most while those of HR-HPV varied the least (Ds>25, p-values<0.001 for VIA, Ds<1.6, p-values>0.05 for HR-HPV). No evidence for correlation between the number of VIAs done per midwife and the variability of VIA results was observed.
The lack of over-dispersion for HR-HPV detection suggests that the variable VIA results do not reflect true variation in underlying disease, but a lack of consistency in human judgement.
传统细胞学检查(巴氏涂片)和应用醋酸后的肉眼观察(VIA)目前用于秘鲁的初次筛查。研究表明,VIA的质量差异很大。在秘鲁亚马逊地区开展的TATI(子宫颈病变的筛查与即时治疗)项目中,超过36000名女性接受了巴氏涂片和VIA检查。在一项比较多种筛查技术的巢式研究(C-TATI)中,另外共有5435名女性接受了液基细胞学检查(LBC)和高危型人乳头瘤病毒检测(HR-HPV)。我们调查了C-TATI中VIA、巴氏涂片、LBC和HR-HPV阳性率的差异以及整个TATI干预中VIA的差异。
在筛查时,助产士在进行VIA之前采集三份宫颈样本用于巴氏涂片、LBC和HC2检测。离散因子“D”(D = 皮尔逊卡方值/自由度)用于衡量检测结果的变异性。在C-TATI中,还通过助产士和筛查月份,用箱线图和散点图对VIA、巴氏涂片、LBC和HR-HPV阳性率的变异性进行了图形评估。采用漏斗图和平滑散点图,将整个TATI干预中每位助产士进行的检查次数与VIA的差异进行关联。
在整个TATI中,VIA结果始终差异很大,与检查者、检查时间以及检查者进行的检查次数无关(D>6,p值<0.001)。在C-TATI中,VIA结果差异最大,而HR-HPV结果差异最小(VIA的Ds>25,p值<0.001;HR-HPV的Ds<1.6,p值>0.05)。未观察到每位助产士进行的VIA检查次数与VIA结果变异性之间存在相关性的证据。
HR-HPV检测缺乏过度离散表明,VIA结果的差异并不反映潜在疾病的真实差异,而是人类判断缺乏一致性。